Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Pneumococcal 13-valent conjugate vaccine (PCV-13) Clear all
Completed No phase listed Observational Results available

A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV

NCT05794191
View directory record Official record
Conditions
HIV, Pneumonia, Infections, Pneumococcal
Interventions
Vaccine Administration
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
350,399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)

NCT03547167
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,515 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
38
States / cities
Chinle, Arizona • Fort Defiance, Arizona • Glendale, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2021 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational

Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia

NCT05007860
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
PCV13 vaccine and any of the FDA-approved COVID-19 vaccine products (BNT162b2, mRNA-1273, or Ad26.COV2.S) based on local availability.
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 6, 2026, 10:13 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age

NCT06855160
View directory record Official record
Conditions
Chickenpox
Interventions
Candidate varicella vaccine, Marketed varicella vaccine, MMR vaccine, Hepatitis A vaccine, PCV (pneumococcal conjugate vaccine) 13, PCV 20, Vaxneuvance
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
911 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
13
States / cities
Tucson, Arizona • Huntington Park, California • Sherman Oaks, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator

NCT04525599
View directory record Official record
Conditions
Healthy Volunteers, Pneumococcal Disease
Interventions
ASP3772, PCV13
Biological
Lead sponsor
Affinivax, Inc.
Industry
Eligibility
12 Months to 15 Months
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
17
States / cities
Bryant, Arkansas • Jonesboro, Arkansas • Anaheim, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Results available

Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines

NCT03530124
View directory record Official record
Conditions
Apnea, Apnea Neonatal, Prematurity
Interventions
PCV13, DTaP, HBV, IPV, Hib
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Weeks and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
4
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 6, 2026, 10:13 PM EDT
Active, not recruiting Phase 2 Interventional

Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy

NCT04745559
View directory record Official record
Conditions
Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL), Follicular Lymphoma
Interventions
Pneumococcal conjugate vaccine (PCV13), CD19 targeted CAR T Cell Therapy
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

NCT01681992
View directory record Official record
Conditions
Measles, Mumps, Rubella, Measles-Mumps-Rubella Vaccine
Interventions
Priorix, M-M-R II, Varivax, Havrix, Prevnar 13
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,538 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Not applicable Interventional Results available

Exploration of Immune Response to Early PCV13 Vaccination in Conjunction With Autologous Transplant

NCT01852591
View directory record Official record
Conditions
Multiple Myeloma
Interventions
PCV 13
Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 2, 2017 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in Aging HIV Positive Adults

NCT03039491
View directory record Official record
Conditions
HIV Lipodystrophy, Aging
Interventions
Pneumococcal polysaccharide vaccine 23 valent, 13 valent conjugated pneumococcal vaccine
Biological
Lead sponsor
Medical University of South Carolina
Other
Eligibility
21 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 6, 2026, 10:13 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

NCT03802994
View directory record Official record
Conditions
Renal Transplantation, Aging
Interventions
23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
Drug · Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 6, 2026, 10:13 PM EDT
Active, not recruiting Not applicable Interventional

Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)

NCT01527591
View directory record Official record
Conditions
Infection in Solid Organ Transplant Recipients
Interventions
Pneumococcal Conjugate Vaccine 13 (PCV13)
Biological
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Months to 59 Months
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine

NCT01654263
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
55 Years to 74 Years
Enrollment
884 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
7
States / cities
Decatur, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 6, 2026, 10:13 PM EDT
Recruiting Phase 1Phase 2 Interventional

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer

NCT03942328
View directory record Official record
Conditions
Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Hepatocellular Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Atezolizumab, Bevacizumab, External Beam Radiation Therapy, Pheresis, Pneumococcal 13-valent Conjugate Vaccine, Therapeutic Autologous Dendritic Cells, Durvalumab, Esophagogastroduodenoscopy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Biopsy Procedure, Biospecimen Collection
Biological · Radiation · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational Results available

FeverText: Assessing Fever Rates After Vaccination During the 2011-12 Influenza Season Using Text Messaging

NCT01467934
View directory record Official record
Conditions
Fever
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
6 Months to 23 Months
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Atlanta, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

NCT03480763
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Pneumonia Vaccine in Aging HIV Positive Individuals

NCT02558751
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
23-valent pneumococcal polysaccharide vaccine, 13-valent pneumococcal conjugate vaccine
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
50 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2015 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months

NCT01000311
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenACWY-CRM, DTaP-IPV/Hib, HBV, PCV, MMR
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
529 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 6, 2026, 10:13 PM EDT
Completed No phase listed Observational

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

NCT03056924
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine
Biological
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 30, 2019 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma

NCT03035331
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Interventions
Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment
Procedure · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine

NCT03803202
View directory record Official record
Conditions
Pneumonia, Bacterial, Healthy Volunteers, Pneumococcal Disease
Interventions
ASP3772, PCV13, PPSV23
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
630 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
26
States / cities
Banning, California • San Diego, California • San Marcos, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 6, 2026, 10:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

NCT01214837
View directory record Official record
Conditions
Meningococcal Disease, Meningococcal Meningitis
Interventions
MenACWY-CRM, Routine Vaccines
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
55 Days to 89 Days
Enrollment
751 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
37
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Oct 6, 2026, 10:13 PM EDT